Summary
The CMV (cisplatin, methotrexate, and vinblastine) and M-VAC (methotrexate, vinblastine, doxorubicin, and cisplatin) regimens were used to treat 19 patients with advanced transitional-cell carcinoma (TCC) of the urothelial tract. In the CMV group, the partial response rate was 45.5% and the mean response duration was 6.3 months. No complete response was obtained in our series. The median duration of survival was 15.8 and 8.3 months in responders and nonresponders, respectively. The toxic symptoms included one case of sepsis and three cases of renal toxicity. However, nausea and vomiting were experienced by most patients and required the administration of antiemetics. In the M-VAC group, the median duration of survival for responders was longer than that of nonresponders (>10.2 vs 7.2 months), although the number of patients was too small for this difference to reach statistical significance. The toxic symptoms included one case of sepsis, two cases of renal toxicity, and nausea and vomiting in most patients. Bone metastasis in three patients did not respond to chemotherapy (CMV), a finding that is compatible with the results reported by other investigators. In summary, chemotherapy with the CMV or M-VAC regimen was effective in improving the response rate of patients. However, the duration of response was short, toxicity was severe in some cases, and the efficacy against bone lesions was poor. These problems must be solved to improve the outcome of patients with TCC following chemotherapy with the CMV or M-VAC regimens.
Similar content being viewed by others
References
Babaian RJ, Johnson DE, Llamas L, Ayala AG (1980) Metastases from transitional cell carcinoma of urinary bladder. Urology 16: 142
Campbell M, Baker LH, Opipari M, Al-Sarraf M (1981) Phase II trial with cisplatin, doxorubicin, and cyclophosphamide (CAP) in the treatment of urothelial transitional cell carcinoma. Cancer Treat Rep 65: 897
Carter SK, Wasserman TH (1975) The chemotherapy of urologic cancer. Cancer 36: 729
deKernion JB (1977) The chemotherapy of advanced bladder carcinoma. Cancer Res 37: 2771
Garnick MB (1989) Chemotherapy and bladder cancer. J Urol 141: 107
Harker WG, Meyers FJ, Freiha FS, Palmer JM, Shortliffe LD, Hannigan FJ, McWhirter KM, Torti FM (1985) Cisplatin, methotrexate and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract: a Northern California Oncology Group study. J Clin Oncol 3: 1463
Herr HW (1980)cis-Diamminedichlorideplatinum(II) in the treatment of advanced bladder cancer. J Urol 123: 853
Igawa M, Ohkuchi T, Ueki T, Ueda M, Okada K, Usui T (1990) Usefulness and limitations of methotrexate, vinblastine, doxorubicin and cisplatin for the treatment of advanced urothelial cancer. J Urol 144: 662
Logothetis CJ, Dexeus FH, Chong C, Sella A, Ayala AG, Ro JY, Pilat S (1989) Cisplatin, cyclophosphamide and doxorubicin chemotherapy for unresectable urothelial tumors: the M. D. Anderson experience. J Urol 141: 33
Merrin C (1978) Treatment of advanced bladder cancer with cis-diamminedichloroplatinum(II) (NSC 119875): a pilot study. J Urol 119: 493
Schwartz S, Yagoda A, Natale RB, Watson RC, Whitmore WF, Lesser M (1983) Phase II trial of sequentially administered cisplatin, cyclophosphamide and doxorubicin for urothelial tract tumors. J Urol 130: 681
Skinner DG (1980) Current perspectives in the management of high-grade invasive bladder cancer. Cancer 45: 1866
Sternberg CN, Yagoda A, Scher HI, Watson RC, Ahmed T, Weiselberg LR, Geller N, Hollander PS, Herr HW, Sogani PC, Morse MJ, Whitmore WF (1985) Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. J Urol 133: 403
Sternberg CN, Yagoda A, Scher HI, Watson RC, Herr HW, Morse MJ, Sogani PC, Vaughan ED Jr, Bander N, Weiselberg LR, Geller N, Hollander PS, Lipperman R, Fair WR, Whitmore WF Jr (1988) M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium. J Urol 139: 461
Troner MB, Hemstreet GP III (1981) Cyclophosphamide, doxorubicin, and cisplatin (CAP) in the treatment of urothelial malignancy: a pilot study of the Southeastern Cancer Study Group. Cancer Treat Rep 65: 29
Turner AG (1981) Methotrexate in advanced bladder cancer. Cancer Treat Rep 65 [Suppl 1]: 183
Yagoda A (1983) Chemotherapy for advanced urothelial cancer. Semin Urol 1: 60
Yagoda A, Watson RC, Gonzalez-Vitale JC, Grabstald H, Whitmore WF (1976)cis-Dichlorodiammineplatinum(II) in advanced bladder cancer. Cancer Treat Rep 60: 917
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lee, MH., Chen, M.T., Chen, K.K. et al. Cisplatin-based chemotherapy for the treatment of advanced transitional-cell carcinoma of the urinary tract — a preliminary report. Cancer Chemother. Pharmacol. 30 (Suppl 1), S81–S84 (1992). https://doi.org/10.1007/BF00686949
Issue Date:
DOI: https://doi.org/10.1007/BF00686949